Atea Pharmaceuticals, Inc.
AVIR
$4.49
$0.143.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 71.30% | 19.89% | 1.41% | -12.08% | -14.76% |
| Gross Profit | -71.30% | -19.89% | -1.41% | 12.08% | 14.76% |
| SG&A Expenses | -34.28% | -32.73% | -16.84% | -11.65% | -6.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.32% | 4.86% | -3.78% | -11.95% | -12.34% |
| Operating Income | -36.32% | -4.86% | 3.78% | 11.95% | 12.34% |
| Income Before Tax | -26.87% | 1.76% | 15.47% | 22.68% | 14.77% |
| Income Tax Expenses | -804.01% | -766.16% | -20.78% | -17.53% | -14.73% |
| Earnings from Continuing Operations | -21.53% | 5.96% | 15.51% | 22.65% | 14.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.53% | 5.96% | 15.51% | 22.65% | 14.77% |
| EBIT | -36.32% | -4.86% | 3.78% | 11.95% | 12.34% |
| EBITDA | -36.43% | -4.88% | 3.79% | 11.98% | 12.37% |
| EPS Basic | -28.75% | 2.38% | 14.34% | 23.25% | 15.73% |
| Normalized Basic EPS | -61.26% | -16.44% | -3.35% | 9.44% | 11.38% |
| EPS Diluted | -28.75% | 2.38% | 14.34% | 23.25% | 15.73% |
| Normalized Diluted EPS | -61.26% | -16.44% | -3.35% | 9.44% | 11.38% |
| Average Basic Shares Outstanding | -5.37% | -3.25% | -1.07% | 0.83% | 1.24% |
| Average Diluted Shares Outstanding | -5.37% | -3.25% | -1.07% | 0.83% | 1.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |